Clinical Trials Browser

Phase 3 × Adenocarcinoma × Imatinib Mesylate × Clear all

NCT00154375 2011-04-26

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Phase 3 Completed

240 enrolled 8 charts

Adenocarcinoma, Astrocytoma, Brain Neoplasms, Glioblastoma